Phase 1 clinical trial unit for therapeutics against infectious diseases

Ended Definitive Contract Awarded Last action

Contract number
HHSN272200800024C
Awardee
Awarding agency
Obligated
$19,644,619

Award facts

Opportunity
Contract value 55% obligated
  • $19,644,619.29 Current, with exercised options
  • $35,575,623.29 Potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00040 -$6,943
Supplemental Agreement for work within scope P00039 -$30,766
Funding Only Action P00038 · Final_close_process -phase 1 clinical trial unit for therapeutics against infectious diseases -$28,669
Other Administrative Action P00037 -$752,040
Other Administrative Action 36 -$18,032
Other Administrative Action 35 -$747,704
Supplemental Agreement for work within scope 34 $0
Supplemental Agreement for work within scope 33 -$935,129
Supplemental Agreement for work within scope 32 -$135,414
Supplemental Agreement for work within scope 31 $68,396
Supplemental Agreement for work within scope 30 $0
Supplemental Agreement for work within scope 29 $0
Supplemental Agreement for work within scope 28 $0
Other Administrative Action 27 $0
Supplemental Agreement for work within scope 26 $30,766
Supplemental Agreement for work within scope 25 $0
Other Administrative Action 24 $0
Exercise an Option 23 $368,621
Exercise an Option 22 $2,059,820
Exercise an Option 21 $1,047,478
Supplemental Agreement for work within scope 20 $706,759
Exercise an Option 19 $286,609
Supplemental Agreement for work within scope 18 $284,513
Exercise an Option 17 $1,487,657
Exercise an Option 16 $2,138,943
Funding Only Action 15 -$386,219
Exercise an Option 14 $508,236
Exercise an Option 13 $618,000
Exercise an Option 12 $493,817
Exercise an Option 11 $2,197,122
Exercise an Option 10 $97,254
Exercise an Option 9 $3,622,483
Exercise an Option 8 $520,000
Other Administrative Action 7 $0
Other Administrative Action 6 $0
Exercise an Option 5 $440,000
Other Administrative Action 4 $0
Exercise an Option 3 $300,000
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $5,409,062
Show all 41

About this award

The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Dynport Vaccine Company LLC for a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases on May 30, 2008, with a ceiling value of $35.6 million and ultimate completion date of June 17, 2019.

The contract employs cost plus fixed fee pricing. Work is performed in Frederick, MD. The solicitation describes establishment and operation of a clinical trial unit to support Phase 1 trials of vaccine and therapeutic candidates targeting infectious diseases. No set-aside was applied to this award.

Dynport Vaccine Company LLC is a subsidiary of General Dynamics Corp.

Quick answers

Who was awarded contract HHSN272200800024C?

HHSN272200800024C was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 30, 2008.

How much is contract HHSN272200800024C worth?

The government has obligated $19,644,619 on HHSN272200800024C. Its potential value, with all options, is $35,575,623.

Was contract HHSN272200800024C competed?

The extent of competition for HHSN272200800024C was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award